Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-α - Induced apoptosis and cell growth arrest

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7545-7553

  Wang, Xiaojian ^a   Li, Nan ^b   Li, Hongzhe ^a   Liu, Bin ^b   Qiu, Jianming ^a   Chen, Taoyong ^b   Cao, Xuetao ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BINDING PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 4; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN MCF 7; ENZYME ACTIVATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING; RNA INTERFERENCE;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 27144557993     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0879     Document Type: Article

References (43)

1. Snyder RD. New concepts in breast cancer therapy. Intern Med J 2004;34:266-9.
2. Losacco T, Ventrella N, Casale F, Logrieco S, Santacroce L. Advances in diagnosis and therapy of breast cancer between the 20th and the 21st centuries. Clin Ther 2004;155:33-40.
3. Garber K. Genomic medicine. Gene expression tests foretell breast cancer's future. Science 2004;303:1754-5.
4. Somerset W, Stout SC, Miller AH, Musselman D. Breast cancer and depression. Oncology 2004;18:1021-34.
5. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-xL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995;182:821-8.
6. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995;55:2576-82.
7. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997;57:1109-15.
8. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet 2003;362:1401-3.
9. Trougakos IP, So A, Jansen B, et al. Silencing expression of the clusterin/apolipoprotein i gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004;64:1834-42.
10. Wang X, Li N, Liu B, et al. A novel human phosphatidylethanolamine- binding protein resists TNFα-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem 2004;279:45855-64.
11. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 2004;305:1471-4.
12. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403-8.
13. Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy 2002;1:327-41.
14. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993;13:4242-50.
15. Yannada T, Hiraoka Y, Ikehata M, et al. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc Natl Acad Sci USA 2004;101:4770-5.
16. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002;99:389-94.
17. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
18. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
19. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UVradiation. J Biol Chem 2000;275:20444-9.
20. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 1998;95:10541-6.
21. Idres N, Benoit G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res 2001;61:700-5.
22. Emoto K, Toyama SN, Karasuyama H, Inoue K, Umeda M. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp Cell Res 1997;232:430-4.
23. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
24. Baud V, Liu ZG, Bennett B, Suzuki N, Xia Y, Karin M. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev 1999;13:1297-308.
25. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-6.
26. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene 2004;23:2809-18.
27. Fuchs SY, Adler V, Buschmann T. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 1998;12:2658-63.
28. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000;275:35778-85.
29. Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710-7.
30. 2/M delays in A549 cells caused by hyperoxia. Exp Cell Res 2004;97:472-83.
31. Yeh PY, Chuang SE, Yeh KH, Song YC, Chang LL, Cheng AL. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004;23:3580-8.
32. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995;270:5511-8.
33. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5598-611.
34. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5588-97.
35. 2/M delays in A549 cells caused by hyperoxia. Oncogene 2004;23:4984-92.
36. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNFα gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999;14:49-57.
37. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000;156:1171-6.
38. Dajee M, Lazarov M, Zhang JY, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-43.
39. Heaney AP, Fernando M, Melmed S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-8.
40. Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ 2003;10:413-7.
41. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981-93.
42. Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-34.
43. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001;21:2743-54.